{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T21:05:10Z","timestamp":1771535110815,"version":"3.50.1"},"reference-count":116,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ccm.2021.11.007","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T06:05:09Z","timestamp":1645941909000},"page":"89-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Nontuberculous Mycobacteria"],"prefix":"10.1016","volume":"43","author":[{"given":"Cara D.","family":"Varley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ccm.2021.11.007_bib1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ccm.2021.11.007_bib2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.ccm.2021.11.007_bib3","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1164\/rccm.201111-2016OC","article-title":"Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries","volume":"185","author":"Adjemian","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.ccm.2021.11.007_bib4","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3201\/eid1510.090196","article-title":"Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998-2005","volume":"15","author":"Billinger","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.007_bib5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3201\/eid1403.061143","article-title":"Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City","volume":"14","author":"Bodle","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"10.1016\/j.ccm.2021.11.007_bib6","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1086\/648443","article-title":"Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology","volume":"49","author":"Cassidy","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1513\/AnnalsATS.201412-559OC","article-title":"Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012","volume":"12","author":"Henkle","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ccm.2021.11.007_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.rmed.2018.10.022","article-title":"Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population","volume":"145","author":"Marras","year":"2018","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib9","first-page":"1007","article-title":"The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey","volume":"135","author":"O'Brien","year":"1987","journal-title":"Am Rev Respir Dis"},{"issue":"7","key":"10.1016\/j.ccm.2021.11.007_bib10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1164\/rccm.201002-0310OC","article-title":"Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems","volume":"182","author":"Prevots","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2021.11.007_bib11","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3201\/eid2206.151642","article-title":"Prevalence of nontuberculous mycobacterial pulmonary disease, Germany, 2009-2014","volume":"22","author":"Ringshausen","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"10.1016\/j.ccm.2021.11.007_bib12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1164\/rccm.201003-0503OC","article-title":"Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease","volume":"182","author":"Winthrop","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","article-title":"Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008-2015","volume":"17","author":"Winthrop","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.007_bib14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3201\/eid2303.161927","article-title":"Pulmonary nontuberculous mycobacteria\u2013associated deaths, Ontario, Canada, 2001\u20132013","volume":"23","author":"Marras","year":"2017","journal-title":"Emerging Infect Dis J"},{"issue":"7","key":"10.1016\/j.ccm.2021.11.007_bib15","first-page":"1112","article-title":"Mortality after respiratory isolation of nontuberculous mycobacteria. A comparison of patients who did and did not meet disease criteria","volume":"14","author":"Novosad","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"10.1016\/j.ccm.2021.11.007_bib16","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1513\/AnnalsATS.201606-474BC","article-title":"Deaths related to nontuberculous mycobacterial infections in the United States, 1999\u20132014","volume":"13","author":"Vinnard","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2672.2009.04161.x","article-title":"Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment","volume":"107","author":"Falkinham","year":"2009","journal-title":"J\u00a0Appl Microbiol"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1164\/rccm.201405-0884OC","article-title":"Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk","volume":"190","author":"Adjemian","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2021.11.007_bib19","first-page":"16","article-title":"Preliminary validation of the NTM module: a patient-reported outcome measure for patients with pulmonary nontuberculous mycobacterial disease","volume":"16","author":"Henkle","year":"2019","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ccm.2021.11.007_bib20","first-page":"1151","article-title":"A\u00a0study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis: clinical characteristics. XX. A report of the Veterans Administration-Armed Forces Cooperative Study on the chemotherapy of tuberculosis","volume":"96","author":"Bates","year":"1967","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1378\/chest.75.2.115","article-title":"Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases","volume":"75","author":"Rosenzweig","year":"1979","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.007_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.genm.2010.01.005","article-title":"Slender, older women appear to be more susceptible to nontuberculous mycobacterial lung disease","volume":"7","author":"Chan","year":"2010","journal-title":"Gend Med"},{"issue":"6","key":"10.1016\/j.ccm.2021.11.007_bib23","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1378\/chest.101.6.1605","article-title":"Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome","volume":"101","author":"Reich","year":"1992","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ccm.2021.11.007_bib24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1164\/ajrccm\/144.4.914","article-title":"Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex","volume":"144","author":"Iseman","year":"1991","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib25","doi-asserted-by":"crossref","first-page":"114916","DOI":"10.1016\/j.diagmicrobio.2019.114916","article-title":"Lady Windermere's counterpart? Pulmonary nontuberculous mycobacteria in men with bronchiectasis","volume":"96","author":"Ku","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.ccm.2021.11.007_bib26","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.meegid.2011.10.006","article-title":"Are phylogenetic position, virulence, drug susceptibility and in\u00a0vivo response to treatment in mycobacteria interrelated?","volume":"12","author":"van Ingen","year":"2012","journal-title":"Infect Genet Evol"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.007_bib27","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/ajrccm.160.3.9811086","article-title":"Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease","volume":"160","author":"Tanaka","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1378\/chest.13-2538","article-title":"Macrolide\/Azalide therapy for nodular\/bronchiectatic mycobacterium avium complex lung disease","volume":"146","author":"Wallace","year":"2014","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1086\/589250","article-title":"Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection","volume":"47","author":"Murray","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.ccm.2021.11.007_bib30","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/rccm.200509-1531OC","article-title":"Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease","volume":"173","author":"Lam","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.007_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.201408-1545OC","article-title":"Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"191","author":"Jeong","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2021.11.007_bib32","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/AAC.04577-14","article-title":"Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciq237","article-title":"Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease","volume":"52","author":"Jarand","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/jamp.2017.1443","article-title":"Impact of hypertonic saline solutions on sputum expectoration and their safety profile in patients with bronchiectasis: a randomized crossover trial","volume":"31","author":"Herrero-Cortina","year":"2018","journal-title":"J\u00a0Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.007_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.rmed.2004.05.006","article-title":"Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis","volume":"99","author":"Kellett","year":"2005","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.ccm.2021.11.007_bib36","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.rmed.2011.07.019","article-title":"Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis","volume":"105","author":"Kellett","year":"2011","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib37","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.rmed.2011.12.021","article-title":"The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis","volume":"106","author":"Nicolson","year":"2012","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.ccm.2021.11.007_bib38","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/j.ajem.2020.08.042","article-title":"The efficacy of inhaled hypertonic saline for bronchiectasis: a meta-analysis of randomized controlled studies","volume":"38","author":"Xie","year":"2020","journal-title":"Am J Emerg Med"},{"issue":"Suppl 2","key":"10.1016\/j.ccm.2021.11.007_bib39","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.007_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","article-title":"Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study","volume":"11","author":"Miwa","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.ccm.2021.11.007_bib41","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201204-0682OC","article-title":"The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment","volume":"186","author":"van Ingen","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.ccm.2021.11.007_bib42","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1086\/433187","article-title":"Conventional and molecular epidemiology of macrolide resistance among new Mycobacterium avium complex isolates recovered from HIV-infected patients","volume":"41","author":"Gardner","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib43","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1164\/ajrccm.149.5.8173775","article-title":"Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease","volume":"149","author":"Wallace","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.007_bib44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drup.2012.04.001","article-title":"Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria","volume":"15","author":"van Ingen","year":"2012","journal-title":"Drug Resist Updat"},{"issue":"4","key":"10.1016\/j.ccm.2021.11.007_bib45","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","article-title":"Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection","volume":"152","author":"Martiniano","year":"2017","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.ccm.2021.11.007_bib46","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/AAC.01240-16","article-title":"Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant mycobacterium avium complex lung disease","volume":"60","author":"Moon","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.ccm.2021.11.007_bib47","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1086\/378807","article-title":"A\u00a0prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome","volume":"37","author":"Benson","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ccm.2021.11.007_bib48","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/infdis\/174.6.1218","article-title":"Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model","volume":"174","author":"Bermudez","year":"1996","journal-title":"J\u00a0Infect Dis"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib49","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1086\/514116","article-title":"A\u00a0randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group","volume":"176","author":"Dub\u00e9","year":"1997","journal-title":"J\u00a0Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.ccm.2021.11.007_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-199700542-00006","article-title":"Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex","volume":"54","author":"Grosset","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.ccm.2021.11.007_bib51","author":"Winthrop"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib52","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.200407-863OC","article-title":"Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease","volume":"172","author":"Griffith","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib53","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4065\/79.5.701","article-title":"Ocular ethambutol toxicity","volume":"79","author":"Herchline","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"284","key":"10.1016\/j.ccm.2021.11.007_bib54","first-page":"57","article-title":"Color vision in 42 Congolese patients with tuberculosis receiving ethambutol treatment","author":"Kaimbo","year":"2002","journal-title":"Bull Soc Belge Ophtalmol"},{"issue":"4","key":"10.1016\/j.ccm.2021.11.007_bib55","doi-asserted-by":"crossref","first-page":"274","DOI":"10.47102\/annals-acadmedsg.V35N4p274","article-title":"Ethambutol-associated optic neuropathy","volume":"35","author":"Lim","year":"2006","journal-title":"Ann Acad Med Singap"},{"issue":"11","key":"10.1016\/j.ccm.2021.11.007_bib56","doi-asserted-by":"crossref","first-page":"e0204655","DOI":"10.1371\/journal.pone.0204655","article-title":"The use of optical coherence tomography for the detection of ocular toxicity by ethambutol","volume":"13","author":"Pavan Taffner","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ccm.2021.11.007_bib57","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000309592","article-title":"Blue-yellow colour vision changes as early symptoms of ethambutol oculotoxicity","volume":"191","author":"Polak","year":"1985","journal-title":"Ophthalmologica"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib58","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tube.2010.02.001","article-title":"Rifamycins\u2013obstacles and opportunities","volume":"90","author":"Aristoff","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib59","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1472-9792(08)70006-4","article-title":"Clofazimine","volume":"88","year":"2008","journal-title":"Tuberculosis (Edinb)"},{"issue":"9","key":"10.1016\/j.ccm.2021.11.007_bib60","first-page":"2968","article-title":"Outcomes of inhaled amikacin and clofazimine-containing regimens for treatment of refractory mycobacterium avium complex pulmonary disease","volume":"9","author":"Kim","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"10.1016\/j.ccm.2021.11.007_bib61","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tube.2004.04.001","article-title":"Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid","volume":"84","author":"Nix","year":"2004","journal-title":"Tuberculosis (Edinb)"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib62","doi-asserted-by":"crossref","first-page":"1801386","DOI":"10.1183\/13993003.01386-2018","article-title":"Clofazimine does not lead to significant QT interval prolongation: a multicentre study","volume":"52","author":"Zweijpfenning","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.007_bib63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","article-title":"Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease","volume":"11","author":"Olivier","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"10.1016\/j.ccm.2021.11.007_bib64","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). a prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2021.11.007_bib65","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2021.11.007_bib66","doi-asserted-by":"crossref","unstructured":"Griffith DE, Thomson R, Addrizzo-Harris DJ, et al. Sustainability and durability of culture conversion in patients receiving amikacin liposome inhalation suspension (ALIS) for treatment-refractory Mycobacterium avium complex lung disease (MAC-LD) in the CONVERT Study. B14 LATE BREAKING CLINICAL TRIALS. American Thoracic Society International Conference Abstracts: American Thoracic Society; May 17-22, 2019 - Dallas, TX, 2019. p. A7359-A","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A7359"},{"issue":"7","key":"10.1016\/j.ccm.2021.11.007_bib67","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1513\/AnnalsATS.202008-925OC","article-title":"Amikacin liposome inhalation suspension for MAC lung disease: a 12-month open-label extension study","volume":"18","author":"Winthrop","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.ccm.2021.11.007_bib68","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jiac.2017.10.022","article-title":"Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens","volume":"24","author":"Cho","year":"2018","journal-title":"J\u00a0Infect Chemother"},{"issue":"11","key":"10.1016\/j.ccm.2021.11.007_bib69","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1128\/AAC.00410-07","article-title":"In\u00a0vitro and in\u00a0vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan","volume":"51","author":"Kohno","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.ccm.2021.11.007_bib70","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1345\/aph.1K347","article-title":"Safety concerns with fluoroquinolones","volume":"41","author":"Mehlhorn","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.007_bib71","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/11531490-000000000-00000","article-title":"Safety considerations of fluoroquinolones in the elderly: an update","volume":"27","author":"Stahlmann","year":"2010","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib72","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40261-017-0498-z","article-title":"Neuropsychiatric effects of antimicrobial agents","volume":"37","author":"Zareifopoulos","year":"2017","journal-title":"Clin Drug Invest"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib73","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01798-16","article-title":"In\u00a0vitro susceptibility testing of bedaquiline against Mycobacterium avium complex","volume":"61","author":"Brown-Elliott","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl_2","key":"10.1016\/j.ccm.2021.11.007_bib74","doi-asserted-by":"crossref","first-page":"i24","DOI":"10.1093\/jac\/dkx304","article-title":"Linezolid as treatment for pulmonary Mycobacterium avium disease","volume":"72","author":"Deshpande","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"suppl_2","key":"10.1016\/j.ccm.2021.11.007_bib75","doi-asserted-by":"crossref","first-page":"i30","DOI":"10.1093\/jac\/dkx305","article-title":"Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease","volume":"72","author":"Deshpande","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib76","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.14-2764","article-title":"Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease","volume":"148","author":"Philley","year":"2015","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.007_bib77","doi-asserted-by":"crossref","first-page":"1601969","DOI":"10.1183\/13993003.01969-2016","article-title":"Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections","volume":"49","author":"Vesenbeckh","year":"2017","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.007_bib78","doi-asserted-by":"crossref","first-page":"1900118","DOI":"10.1183\/13993003.00118-2019","article-title":"Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease","volume":"54","author":"Zweijpfenning","year":"2019","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.ccm.2021.11.007_bib79","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jiac.2014.05.010","article-title":"Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy","volume":"20","author":"Jo","year":"2014","journal-title":"J\u00a0Infect Chemother"},{"issue":"4","key":"10.1016\/j.ccm.2021.11.007_bib80","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1183\/09031936.00169114","article-title":"The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease","volume":"45","author":"Winthrop","year":"2015","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ccm.2021.11.007_bib81","first-page":"353","article-title":"Linezolid and serotonin syndrome","volume":"11","author":"Quinn","year":"2009","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib82","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1128\/JCM.02087-16","article-title":"Emergence of mmpT5 variants during bedaquiline treatment of Mycobacterium intracellulare lung disease","volume":"55","author":"Alexander","year":"2017","journal-title":"J\u00a0Clin Microbiol"},{"issue":"11","key":"10.1016\/j.ccm.2021.11.007_bib83","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccm.2021.11.007_bib84","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/ajrccm.165.2.2107025","article-title":"Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs","volume":"165","author":"Goldstein","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.007_bib85","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijantimicag.2013.04.029","article-title":"Further isolation of Mycobacterium abscessus subsp. abscessus and subsp. bolletii in different regions of Japan and susceptibility of these isolates to antimicrobial agents","volume":"42","author":"Yoshida","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.ccm.2021.11.007_bib86","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1128\/JCM.01257-09","article-title":"Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France","volume":"47","author":"Roux","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib87","first-page":"324","article-title":"Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients","volume":"59","author":"van Ingen","year":"2009","journal-title":"J\u00a0Infect"},{"issue":"7","key":"10.1016\/j.ccm.2021.11.007_bib88","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1128\/JCM.01688-08","article-title":"Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii","volume":"47","author":"Zelazny","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"issue":"6","key":"10.1016\/j.ccm.2021.11.007_bib89","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1378\/chest.12-0494","article-title":"Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease","volume":"142","author":"Koh","year":"2012","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.ccm.2021.11.007_bib90","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1128\/JCM.01132-13","article-title":"New rapid scheme for distinguishing the subspecies of the Mycobacterium abscessus group and identifying Mycobacterium massiliense isolates with inducible clarithromycin resistance","volume":"51","author":"Shallom","year":"2013","journal-title":"J\u00a0Clin Microbiol"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib91","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1128\/AAC.00861-10","article-title":"Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing","volume":"55","author":"Bastian","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.ccm.2021.11.007_bib92","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1348-0421.2010.00221.x","article-title":"Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns","volume":"54","author":"Kim","year":"2010","journal-title":"Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.007_bib93","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5588\/ijtld.15.0068","article-title":"Subspecies distribution and macrolide and fluoroquinolone resistance genetics of Mycobacterium abscessus in Korea","volume":"20","author":"Kim","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.007_bib94","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.diagmicrobio.2017.11.001","article-title":"In\u00a0vitro activity of tedizolid against the Mycobacterium abscessus complex","volume":"90","author":"Compain","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.007_bib95","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.diagmicrobio.2017.09.013","article-title":"In\u00a0vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex","volume":"90","author":"Zhang","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib96","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02627-16","article-title":"In\u00a0vitro activity of bedaquiline against nontuberculous mycobacteria in China","volume":"61","author":"Pang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.ccm.2021.11.007_bib97","doi-asserted-by":"crossref","first-page":"ofaa415","DOI":"10.1093\/ofid\/ofaa415","article-title":"Omadacycline for the treatment of Mycobacterium abscessus disease: a case series","volume":"7","author":"Pearson","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"10.1016\/j.ccm.2021.11.007_bib98","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.ccm.2021.11.007_bib99","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/cid\/ciz1014","article-title":"Omadacycline in the treatment of Mycobacterium abscessus infection","volume":"71","author":"Madariaga","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.007_bib100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01947-20","article-title":"<em>In\u00a0vitro<\/em> susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"65","author":"Brown-Elliott","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.ccm.2021.11.007_bib101","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00470-19","article-title":"In\u00a0vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ccm.2021.11.007_bib102","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02522-18","article-title":"In\u00a0vitro activities of omadacycline against rapidly growing mycobacteria","volume":"63","author":"Shoen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.ccm.2021.11.007_bib103","first-page":"e5112","article-title":"Utilizing the promise of omadacycline in a resistant, non-tubercular mycobacterial pulmonary infection","volume":"11","author":"Minhas","year":"2019","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib104","doi-asserted-by":"crossref","first-page":"ofab002","DOI":"10.1093\/ofid\/ofab002","article-title":"Preliminary, real-world, multicenter experience with omadacycline for Mycobacterium abscessus infections","volume":"8","author":"Morrisette","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.ccm.2021.11.007_bib105","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/jac\/dku062","article-title":"Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections","volume":"69","author":"Wallace","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.ccm.2021.11.007_bib106","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1128\/AAC.00685-12","article-title":"Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense","volume":"56","author":"Choi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.007_bib107","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1128\/AAC.34.1.65","article-title":"Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy","volume":"34","author":"Wallace","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccm.2021.11.007_bib108","doi-asserted-by":"crossref","unstructured":"Siegel S, Clock JA, Hoeft J, et al. Open-Label trial of amikacin liposome inhalation suspension in M. abscessus lung disease. B19 ADVANCES IN the treatment OF NTM. American Thoracic Society International Conference Abstracts: American Thoracic Society; May 17-22, 2019 - Dallas, TX, 2019. p. A2653-A.","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A2653"},{"issue":"4","key":"10.1016\/j.ccm.2021.11.007_bib109","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1183\/20734735.027218","article-title":"Surgery in nontuberculous mycobacteria pulmonary disease","volume":"14","author":"Lu","year":"2018","journal-title":"Breathe"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0003-4975(98)00401-9","article-title":"Results of operation in <em>Mycobacterium avium-intracellulare<\/em> lung disease","volume":"66","author":"Nelson","year":"1998","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.007_bib111","first-page":"99","article-title":"Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time","volume":"14","author":"van Ingen","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.007_bib112","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12879-015-0823-1","article-title":"Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease","volume":"15","author":"Kang","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.007_bib113","first-page":"671","article-title":"Lady Windermere revisited: treatment with thoracoscopic lobectomy\/segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease","volume":"40","author":"Yu","year":"2011","journal-title":"Eur J Cardiothorac Surg"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.007_bib114","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3346\/jkms.2008.23.3.397","article-title":"Surgical treatment of pulmonary diseases due to nontuberculous mycobacteria","volume":"23","author":"Koh","year":"2008","journal-title":"J\u00a0Korean Med Sci"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib115","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.athoracsur.2004.02.103","article-title":"Pneumonectomy for nontuberculous mycobacterial infections","volume":"78","author":"Shiraishi","year":"2004","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.007_bib116","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S1010-7940(01)01122-8","article-title":"Surgery for Mycobacterium avium complex lung disease in the clarithromycin era","volume":"21","author":"Shiraishi","year":"2002","journal-title":"Eur J Cardiothorac Surg"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523121012454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523121012454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:15:25Z","timestamp":1759454125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523121012454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0272523121012454"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2021.11.007","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nontuberculous Mycobacteria","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2021.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}